Glucocorticoid dysregulations and their clinical correlates: From receptors to therapeutics

Annals of the New York Academy of Sciences

Volumn 1179, Issue , 2009, Pages 1-18

  Marques, Andrea H ^a   Silverman, Marni N ^a   Sternberg, Esther M ^a  

^a NIMH/NIH   (United States)

Author keywords

Cortisol; Cytokines; Depression; Glucocorticoid resistance; HPA axis; Inflammation; Psychosis

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; ALPHA INTERFERON; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; BIOLOGICAL MARKER; CORTICOTROPIN RELEASING FACTOR; CYTOKINE; DEXAMETHASONE; ESTROGEN; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; GLYCOPROTEIN P; HYDROCORTISONE; PROGESTERONE; TRANSCORTIN;

BEDTIME DOSAGE; BEHAVIOR; BRAIN FUNCTION; COGNITION; CONFERENCE PAPER; CYTOKINE RELEASE; DEPRESSION; DEXAMETHASONE SUPPRESSION TEST; DRUG RECEPTOR BINDING; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HEPATITIS C; HORMONE RELEASE; HUMAN; HYPOMANIA; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MAJOR DEPRESSION; MEMORY; METABOLIC SYNDROME X; MOOD; MOOD CHANGE; NEOPLASM; NONHUMAN; OSTEOLYSIS; POSTTRAUMATIC STRESS DISORDER; PROTEIN EXPRESSION; SIDE EFFECT; SINGLE DRUG DOSE; SUICIDE; SYMPTOMATOLOGY;

ANIMALS; COGNITION DISORDERS; DEPRESSIVE DISORDER; FORECASTING; GLUCOCORTICOIDS; GONADAL STEROID HORMONES; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; PITUITARY-ADRENAL SYSTEM; RECEPTORS, GLUCOCORTICOID;

EID: 70449386843     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.04987.x     Document Type: Conference Paper

References (152)

1. The Boston Collaborative Drug Surveillance Program. 1972. Acute adverse reactions to prednisone in relation to dosage. Clin. Pharmacol. Ther. 13: 694-698.
2. Wolkowitz, O.M. 1994. Prospective controlled studies of the behavioral and biological effects of exogenous corticosteroids. Psychoneuroendocrinology 19: 233-255.
3. Wolkowitz, O., et at. Mood, memory, and mechanisms. Ann. N. Y. Acad. Sci. Glucocorticoids and Mood: Clinical Manifestations, Risk Factors, and Molecular Mechanisms. In press.
4. Brown, E.S. 2009. Effects of glucocorticoids on mood, memory, and the hippocampus: treatment and preventive therapy. Ann. N. Y. Acad. Sci. Glucocorticoids and Mood: Clinical Manifestations, Risk Factors, and Molecular Mechanisms. In press.
5. Wolkowitz,O.M. et al. 2004. The "steroid dementia syndrome": an unrecognized complication of glucocorticoid treatment. Ann. N. Y. Acad. Sci. 1032: 191-194.
6. Wolkowitz, O.M., S.J. Lupien & E.D. Bigler. 2007. The "steroid dementia syndrome": a possiblemodel of human glucocorticoid neurotoxicity. Neurocase 13: 189-200.
7. Brown, E.S. & T. Suppes. 1998. Mood symptoms during corticosteroid therapy: a review. Harv. Rev. Psychiatry 5: 239-246.
8. Lewis, D.A. & R.E. Smith. 1983. Steroid-induced psychiatric syndromes. A report of 14 cases and a review of the literature. J. Affect. Disord. 5: 319-332.
9. Brown, E.S. et al. 2005. Effect of phenytoin on mood and declarative memory during prescription corticosteroid therapy. Biol. Psychiatry 57: 543-548.
10. Brown, E.S. et al. 2008. Attenuation of the effects of corticosteroids on declarative memory with lamotrigine. Neuropsychopharmacology 33: 2376-2385.
11. Fava, G.A. 1994. Affective disorders and endocrine disease. New insights from psychosomatic studies. Psychosomatics 35: 341-353.
12. Frank, R. & H.G. Doerr. 1989. Mania in a girl with Cushing's disease. J. Am. Acad. Child. Adolesc. Psychiatry 28: 610-611.
13. Ghadirian, A.M., S.Marcovitz&B.E. Pearson Murphy. 2005. A case of seasonal bipolar disorder exacerbated by Cushing's disease. Compr. Psychiatry 46: 155-158.
14. Haskett, R.F. 1985. Diagnostic categorization of psychiatric disturbance in Cushing's syndrome. Am. J. Psychiatry 142: 911-916.
15. Borzyskowski, M., D.B. Grant & R.S. Wells. 1976. Cushing's syndrome induced by topical steroids used for the treatment of non-bullous ichthyosiform erythroderma. Clin. Exp. Dermatol. 1: 337-342.
16. Guven, A., O. Gulumser & T. Ozgen. 2007. Cushing's syndrome and adrenocortical insufficiency caused by topical steroids:misuse or abuse? J. Pediatr. Endocrinol. Metab. 20: 1173-1182.
17. Ruiz-Maldonado, R. et al. 1982. Cushing's syndrome after topical application of corticosteroids. Am. J. Dis. Child. 136: 274-275.
18. Juruena, M.F., A.J. Cleare & C.M. Pariante. 2004. [The hypothalamic pituitary adrenal axis, glucocorticoid receptor function and relevance to depression]. Rev. Bras. Psiquiatr. 26: 189-201.
19. Chrousos, G.P. & T. Kino. 2007. Glucocorticoid action networks and complex psychiatric and/or somatic disorders. Stress 10: 213-219.
20. Holsboer, F. & M. Ising. 2008. Central CRH system in depression and anxiety-evidence from clinical studies with CRH1 receptor antagonists. Eur. J. Pharmacol. 583: 350-357.
21. Calfa, G. et al. 2003. Characterization and functional significance of glucocorticoid receptors in patients with major depression: modulation by antidepressant treatment. Psychoneuroendocrinology 28: 687-701.
22. Linkowski, P. et al. 1987. 24-hour profiles of adrenocorticotropin, cortisol, and growth hormone in major depressive illness: effect of antidepressant treatment. J. Clin. Endocrinol. Metab. 65: 141-152.
23. Pariante, C.M. 2004. Glucocorticoid receptor function in vitro in patients with major depression. Stress 7: 209-219.
24. Pariante, C.M. 2009. Risk factors for development of depression and psychosis: glucocorticoid receptors and pituitary implications for treatment with antidepressant and glucocorticoids. Ann. N. Y. Acad. Sci. Glucocorticoids andMood: Clinical Manifestations, Risk Factors, and Molecular Mechanisms. In press.
25. DeBattista, C. et al. 2000. Acute antidepressant effects of intravenous hydrocortisone and CRH in depressed patients: a double-blind, placebo-controlled study. Am. J. Psychiatry 157: 1334-1337.
26. Wolkowitz, O.M. & V.I. Reus. 1999. Treatment of depression with antiglucocorticoid drugs. Psychosom. Med. 61: 698-711.
27. Bouwer, C. et al. 2000. Prednisone augmentation in treatment-resistant depression with fatigue and hypocortisolaemia: a case series. Depress Anxiety 12: 44-50.
28. Dinan, T.G. et al. 1997. Dexamethasone augmentation in treatment-resistant depression. Acta. Psychiatr. Scand. 95: 58-61.
29. Reus, V.I. & O.M. Wolkowitz. 2001. Antiglucocorticoid drugs in the treatment of depression. Expert Opin. Investig. Drugs 10: 1789-1796.
30. Schatzberg, A.F. & S. Lindley. 2008. Glucocorticoid antagonists in neuropsychotic disorders. Eur. J. Pharmacol. 583: 358-364.
31. Wolkowitz O.M. et al. Dexamethasone for depression Am. J. Psychiatry 153 1112 author reply 1112-1113
32. Chrousos, G.P. & T. Kino. 2009. Glucocorticoid signaling in the cell: expanding clinical implications to complex human behavioral and somatic disorders. Ann. N. Y. Acad. Sci. Glucocorticoids andMood: Clinical Manifestations, Risk Factors, and Molecular Mechanisms. In press.
33. Hauger, R.L., et at. 2009. Role of CRF receptor signaling in stress vulnerability, anxiety, and depression. Ann. N. Y. Acad. Sci. Glucocorticoids andMood: Clinical Manifestations, Risk Factors, and Molecular Mechanisms. In press.
34. Refojo, D. & F. Holsboer. 2009. CRH signaling: molecular specificity for drug targeting in the central nervous system. Ann. N. Y. Acad. Sci. Glucocorticoids and Mood: Clinical Manifestations, Risk Factors, and Molecular Mechanisms. In press.
35. Manenschijn, L., et at. 2009. Clinical features associated with glucocorticoid receptor polymorphisms: an overview. Ann. N. Y. Acad. Sci. Glucocorticoidsand Mood: Clinical Manifestations, Risk Factors, and Molecular Mechanisms. In press.
36. Spijker, A.T. & E.F.C. Van Rossum. 2009. Glucocorticoid receptor polymorphisms in major depression: focus on glucocorticoid sensitivity and neurocognitive functioning. Ann. N. Y. Acad. Sci. Glucocorticoids and Mood: Clinical Manifestations, Risk Factors, and Molecular Mechanisms. In press.
37. Van Den Akker, E.L. et al. 2008. Glucocorticoid receptor gene and risk of cardiovascular disease. Arch. Intern. Med. 168: 33-39.
38. Van Rossum, E.F. et al. 2006. Polymorphisms of the glucocorticoid receptor gene and major depression. Biol. Psychiatry 59: 681-688.
39. Van Rossum, E.F. et al. 2008. Glucocorticoid receptor variant and risk of dementia and white matter lesions. Neurobiol. Aging 29: 716-723.
40. Van Rossum, E.F. et al. 2003. Identification of the BclI polymorphism in the glucocorticoid receptor gene: association with sensitivity to glucocorticoids in vivo and body mass index. Clin. Endocrinol. (Oxf.) 59: 585-592.
41. Van Rossum, E.F. & S.W. Lamberts. 2004. Polymorphisms in the glucocorticoid receptor gene and their associations with metabolic parameters and body composition. Recent Prog. Horm. Res. 59: 333-357.
42. Van Rossum, E.F., H. Russcher & S.W. Lamberts. 2005. Genetic polymorphisms and multifactorial diseases: facts and fallacies revealed by the glucocorticoid receptor gene. Trends Endocrinol.Metab. 16: 445-450.
43. Van West, D. et al. 2006. Glucocorticoid receptor gene-based SNP analysis in patients with recurrent major depression. Neuropsychopharmacology 31: 620-627.
44. Silverman, M.N. et al. 2005. Immune modulation of the hypothalamic-pituitary-adrenal (HPA) axis during viral infection. Viral. Immunol. 18: 41-78.
45. Sternberg, E.M. 2006. Neural regulation of innate immunity: a coordinated nonspecific host response to pathogens. Nat. Rev. Immunol. 6: 318-328.
46. Marques-Deak, A., G. Cizza & E. Sternberg. 2005. Brain-immune interactions and disease susceptibility. Mol. Psychiatry 10: 239-250.
47. Dantzer, R. et al. 2008. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci. 9: 46-56.
48. Raison, C.L., L. Capuron & A.H. Miller. 2006. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 27: 24-31.
49. Sapolsky, R.M., L.M. Romero & A.U. Munck. 2000. How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions. Endocr. Rev. 21: 55-89.
50. Jacobson, L. 2005. Hypothalamic-pituitaryadrenocortical axis regulation. Endocrinol. Metab. Clin. North Am. 34: 271-292, vii.
51. Keller-Wood, M.E. & M.F. Dallman. 1984. Corticosteroid inhibition of ACTH secretion. Endocr. Rev. 5: 1-24.
52. Herman, J.P. et al. 1989. Evidence for hippocampal regulation of neuroendocrine neurons of the hypothalamo-pituitary-adrenocortical axis. J. Neurosci. 9: 3072-3082.
53. Rosner, W. 1991. Plasma steroid-binding proteins. Endocrinol. Metab. Clin. North Am. 20: 697-720.
54. Tinnikov, A.A. et al. 1993. Serum corticosteroidbinding globulin levels in children undergoing heart surgery. Steroids 58: 536-539.
55. Deuschle, M. et al. 2003. Increased concentration of corticosteroid- binding globulin due to antidepressant treatment with amitritpyline, but not paroxetine. J. Psychiatr. Res. 37: 85-87.
56. Chin, K.V. et al. 1990.Regulation of mdrRNAlevels in response to cytotoxic drugs in rodent cells. Cell Growth Differ. 1: 361-365.
57. Karssen, A.M. et al. 2001. Multidrug resistance Pglycoprotein hampers the access of cortisol but not of corticosterone to mouse and human brain. Endocrinology 142: 2686-2694.
58. Silverman, M.N. & E.M. Sternberg. 2008. Neuroendocrine-immune interactions in rheumatoid arthritis: mechanisms of glucocorticoid resistance. Neuroimmunology 15: 19-28.
59. Hirano, T. et al. 2004. MDR1 mRNA expressions in peripheral blood mononuclear cells of patients with ulcerative colitis in relation to glucocorticoid administration. J. Clin. Pharmacol. 44: 481-486.
60. Maillefert, J.F. et al. 1996. Expression of the multidrug resistance glycoprotein 170 in the peripheral blood lymphocytes of rheumatoid arthritis patients. The percentage of lymphocytes expressing glycoprotein 170 is increased in patients treated with prednisolone. Br. J. Rheumatol. 35: 430-435.
61. Pariante, C.M. 2008. The role of multi-drug resistance p-glycoprotein in glucocorticoid function: studies in animals and relevance in humans. Eur. J. Pharmacol. 583: 263-271.
62. Pariante,C.M. et al. 2003. Antidepressant fluoxetine enhances glucocorticoid receptor function in vitro by modulating membrane steroid transporters. Br. J. Pharmacol. 139: 1111-1118.
63. Laika, B., S. Leucht & W. Steimer. 2006. ABCB1 (P-glycoprotein/MDR1) gene G2677T/a sequence variation (polymorphism): lack of association with side effects and therapeutic response in depressedinpatients treated with amitriptyline. Clin. Chem. 52: 893-895.
64. Mihaljevic Peles, A. et al. 2008. MDR1 gene polymorphism: therapeutic response to paroxetine among patients with major depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 32: 1439-1444.
65. Seckl, J.R. & B.R. Walker. 2001. Minireview: 11beta-hydroxysteroid dehydrogenase type 1-a tissue-specific amplifier of glucocorticoid action. Endocrinology 142: 1371-1376.
66. Chapman, K.E. & J.R. Seckl. 2008. 11beta-HSD1, inflammation, metabolic disease and age-related cognitive (dys)function. Neurochem. Res. 33: 624-636.
67. Mc Ewen, B.S. 2007. Physiology and neurobiology of stress and adaptation: central role of the brain. Physiol. Rev. 87: 873-904.
68. Poor, V. et al. 2004. Urinary steroid metabolites and 11beta-hydroxysteroid dehydrogenase activity in patients with unipolar recurrent major depression. J. Affect Disord. 81: 55-59.
69. Weber, B. et al. 2000. Increased diurnal plasma concentrations of cortisone in depressed patients. J. Clin. Endocrinol. Metab. 85: 1133-1136.
70. Duma,D., C.M. Jewell&J.A.Cidlowski. 2006. Multiple glucocorticoid receptor isoforms and mechanisms of post-translational modification. J. Steroid Biochem. Mol. Biol. 102: 11-21.
71. Joels, M. et al. 2008. The coming out of the brain mineralocorticoid receptor. Trends Neurosci. 31: 1-7.
72. Revollo, J.R. & J.A. Cidlowski. 2009. Mechanisms generating diversity in glucocorticoid receptor signaling. Ann. N. Y. Acad. Sci. Glucocorticoids and Mood: Clinical Manifestations, Risk Factors, and Molecular Mechanisms. In press.
73. Kassel, O. & P. Herrlich. 2007. Crosstalk between the glucocorticoid receptor and other transcription factors: molecular aspects. Mol. Cell. Endocrinol. 275: 13-29.
74. Liberman, A.C. et al. 2007. Glucocorticoids in the regulation of transcription factors that control cytokine synthesis. Cytokine Growth Factor Rev. 18: 45-56.
75. Liberman, A.C. et al. 2007. The activated glucocorticoid receptor inhibits the transcription factor T-bet by direct protein-protein interaction. FASEB J. 21: 1177-1188.
76. Rhen, T. & J.A. Cidlowski. 2005. Antiinflammatory action of glucocorticoids-new mechanisms for old drugs. N. Engl. J. Med. 353: 1711-1723.
77. Tait, A.S., C.L. Butts & E.M. Sternberg. 2008. The role of glucocorticoids and progestins in inflammatory, autoimmune, and infectious disease. J. Leukoc. Biol. 84: 924-931.
78. Pace, T.W., F. Hu & A.H. Miller. 2007. Cytokineeffects on glucocorticoid receptor function: relevance to glucocorticoid resistance and the pathophysiology and treatment ofmajor depression. Brain Behav. Immun. 21: 9-19.
79. Miller, G.E. et al. 2008. A functional genomic fingerprint of chronic stress in humans: blunted glucocorticoid and increased NF-kappaB signaling Biol. Psychiatry 64: 266-272.
80. Pace, T.W. et al. 2006. Increased stress-induced inflammatory responses in male patients with major depression and increased early life stress. Am. J. Psychiatry 163: 1630-1633.
81. Colli, L.M. et al. 2007. Interindividual glucocorticoid sensitivity in young healthy subjects: the role of glucocorticoid receptor alpha and beta isoforms ratio. Horm. Metab. Res. 39: 425-429.
82. Tliba, O., J.A. Cidlowski & Y. Amrani. 2006. CD38 expression is insensitive to steroid action in cells treated with tumor necrosis factor-alpha and interferon-gamma by a mechanism involving the up-regulation of the glucocorticoid receptor beta isoform. Mol. Pharmacol. 69: 588-596.
83. Derijk, R.H. et al. 2001. A human glucocorticoid receptor gene variant that increases the stability of the glucocorticoid receptor beta-isoform mRNA is associated with rheumatoid arthritis. J. Rheumatol. 28: 2383-2388.
84. Lee, Y.M. et al. 2004. A mutation of the glucocorticoid receptor gene in patients with systemic lupus erythematosus. Tohoku J. Exp. Med. 203: 69-76.
85. Claes, S. 2009. Glucocorticoid receptor polymorphisms in major depression. Ann. N. Y. Acad. Sci. Glucocorticoids and Mood: Clinical Manifestations, Risk Factors, and Molecular Mechanisms. In press.
86. Wassef, A. et al. 1990. Mononuclear leukocyte glucocorticoid receptor binding characteristics and down-regulation in major depression. Psychoneuroendocrinology 15: 59-68.
87. Bauer, M.E. et al. 2003. Altered glucocorticoid immunoregulation in treatment resistant depression. Psychoneuroendocrinology 28: 49-65.
88. Lowy, M.T. et al. 1984. Glucocorticoid resistance in depression: the dexamethasone suppression test and lymphocyte sensitivity to dexamethasone. Am. J. Psychiatry 141: 1365-1370.
89. Miller, G.E. et al. 2005. Clinical depression and regulation of the inflammatory response during acute stress. Psychosom. Med. 67: 679-687.
90. Wodarz, N. et al. 1991. Normal lymphocyte responsiveness to lectins but impaired sensitivity to in vitro glucocorticoids in major depression. J. Affect. Disord. 22: 241-248.
91. Antonijevic, I.A. 2006. Depressive disorders-is it time to endorse different pathophysiologies? Psychoneuroendocrinology 31: 1-15.
92. Holsboer, F. 2000. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 23: 477-501.
93. Aihara, M. et al. 2007. HPA axis dysfunction in unmedicated major depressive disorder and its normalization by pharmacotherapy correlates with alteration of neural activity in prefrontal cortex and limbic/paralimbic regions. Psychiatry Res. 155: 245-256.
94. Kaestner, F. et al. 2005. Different activation patterns of proinflammatory cytokines in melancholic and non-melancholic major depression are associated with HPA axis activity. J. Affect. Disord. 87: 305-311.
95. Michael, R.P. & J.L. Gibbons. 1963. Interrelationships between the Endocrine System Neuropsychiatry. Int. Rev. Neurobiol. 5: 243-302.
96. Carroll, B.J. et al. 2007. Pathophysiology of hypercortisolism in depression. Acta Psychiatr. Scand. Suppl. 433: 90-103.
97. Nemeroff, C.B. 1996. The corticotropin-releasing factor (CRF) hypothesis of depression: new findings and new directions. Mol. Psychiatry 1: 336-342.
98. Pariante,C.M.&A.H. Miller. 2001. Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol. Psychiatry 49: 391-404.
99. Owens, M.J. & C.B. Nemeroff. 1993. The role of corticotropin- releasing factor in the pathophysiology of affective and anxiety disorders: laboratory and clinical studies. Ciba. Found Symp. 172: 296-308; discussion 308-316.
100. Holsboer, F. 2003. Corticotropin-releasing hormone modulators and depression. Curr. Opin. Investig. Drugs 4: 46-50.
101. Roy, A. et al. 1987. CSF corticotropin-releasing hormone in depressed patients and normal control subjects. Am. J. Psychiatry 144: 641-645.
102. Pariante, C.M. et al. 2004. Pituitary volume in psychosis. Br. J. Psychiatry 185: 5-10.
103. Merali, Z. et al. 2004. Dysregulation in the suicide brain: mRNA expression of corticotropin-releasing hormone receptors and GABA(A) receptor subunits in frontal cortical brain region. J. Neurosci. 24: 1478-1485.
104. Raadsheer, F.C. et al. 1994. Increased numbers of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of depressed patients. Neuroendocrinology 60: 436-444.
105. Deuschle, M. et al. 1997. Diurnal activity and pulsatility of the hypothalamus-pituitary-adrenal system inmale depressed patients and healthy controls. J. Clin. Endocrinol. Metab. 82: 234-238.
106. Ribeiro, S.C. et al. 1993. The DST as a predictor of outcome in depression: a meta-analysis. Am. J. Psychiatry 150: 1618-1629.
107. Pariante,C.M. et al. 2002.Anovel prednisolone suppression test for the hypothalamic-pituitary-adrenal axis. Biol. Psychiatry 51: 922-930.
108. Watson, S. et al. 2006. The dex/CRH test-is it better than the DST? Psychoneuroendocrinology 31: 889-894.
109. Hatzinger, M. et al. 2002. The combined DEXCRH test in treatment course and long-term outcome of major depression. J. Psychiatr. Res. 36: 287-297.
110. Zobel, A.W. et al. 2001. Cortisol response in the combined dexamethasone/CRH test as predictor of relapse in patients with remitted depression. A prospective study. J. Psychiatr. Res. 35: 83-94.
111. Lan, N.C. et al. 1982. Binding of steroids to mineralocorticoid receptors: implications for in vivo occupancy by glucocorticoids. J. Clin. Endocrinol. Metab. 54: 332-342.
112. Pugeat, M.M., J.F. Dunn & B.C. Nisula. 1981. Transport of steroid hormones: interaction of 70 drugs with testosterone-binding globulin and corticosteroid-binding globulin in human plasma. J. Clin. Endocrinol. Metab. 53: 69-75.
113. Lac, G. et al. 1999. Dexamethasone in resting and exercising men. II. Effects on adrenocortical hormones. J. Appl. Physiol. 87: 183-188.
114. Juruena, M.F. et al. 2006. Different responses to dexamethasone and prednisolone in the same depressed patients. Psychopharmacology (Berl.) 189: 225-235.
115. Young, E.A. & N. Breslau. 2004. Saliva cortisol in posttraumatic stress disorder: a community epidemiologic study. Biol. Psychiatry 56: 205-209. (Pubitemid 38969154)
116. Heim, C. et al. 2000. Pituitary-adrenal and autonomic responses to stress in women after sexual and physical abuse in childhood. JAMA 284: 592-597.
117. Mello, A.F. et al. 2007. [Depression and stress: is there an endophenotype?]. Rev. Bras. Psiquiatr. 29(Suppl 1): S13-S18.
118. Belanoff, J.K. et al. 2002. An open label trial of C- 1073 (mifepristone) for psychotic major depression. Biol. Psychiatry 52: 386-392.
119. Schatzberg, A.F. et al. 2000. Neuropsychological deficits in psychotic versus nonpsychotic major depression and no mental illness. Am. J. Psychiatry 157: 1095-1100.
120. Bremmer, M.A. et al. 2007. Major depression in late life is associated with both hypo- and hypercortisolemia. Biol. Psychiatry 62: 479-486.
121. Yehuda, R. 2009. Status of glucocorticoid alterations in Post-traumatic stress disorder. Ann. N. Y.Acad. Sci. Glucocorticoids andMood: Clinical Manifestations, Risk Factors, and Molecular Mechanisms. In press.
122. Yehuda,R. 2002. Clinical relevance of biologic findings in PTSD. Psychiatr. Q. 73: 123-133.
123. Burgess, L.H. & R.J. Handa. 1992. Chronic estrogen-induced alterations in adrenocorticotropin and corticosterone secretion, and glucocorticoid receptor-mediated functions in female rats. Endocrinology 131: 1261-1269.
124. Miller, W.J. et al. 2004. Estrogen receptor (ER)beta isoforms rather than ERalpha regulate corticotropin-releasing hormone promoter activity through an alternate pathway. J. Neurosci. 24: 10628-10635.
125. Schmidt, P.J. & D.R. Rubinow. 2009. Sex hormones and mood in the perimenopause. Ann. N. Y. Acad. Sci. Glucocorticoids andMood: Clinical Manifestations, Risk Factors, and Molecular Mechanisms. In press.
126. Daly, R.C. et al. 2003. Concordant restoration of ovarian function and mood in perimenopausal depression. Am. J. Psychiatry 160: 1842-1846.
127. Roca, C.A. et al. 2003. Differential menstrual cycle regulation of hypothalamic-pituitary-adrenal axis in women with premenstrual syndrome and controls. J. Clin. Endocrinol. Metab. 88: 3057-3063.
128. Pace, T.W.W. & A.H. Miller. 2009. Cytokines and glucocorticoid receptor signaling: relevance to major depression. Ann. N. Y. Acad. Sci. Glucocorticoids and Mood: Clinical Manifestations, Risk Factors, and Molecular Mechanisms. In press.
129. Adcock, I.M. & K. Ito. 2000. Molecular mechanisms of corticosteroid actions. Monaldi. Arch. Chest. Dis. 55: 256-266.
130. Barnes, P.J. 1998. Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin. Sci. (Lond.) 94: 557-572.
131. Elenkov, I.J. 2004. Glucocorticoids and the Th1/Th2 balance. Ann. N. Y. Acad. Sci. 1024: 138-146.
132. Black, P.H. 2003. The inflammatory response is an integral part of the stress response: implications for atherosclerosis, insulin resistance, type II diabetes and metabolic syndrome X. Brain Behav. Immun. 17: 350-364.
133. Kiecolt-Glaser, J.K. & R. Glaser. 2002. Depression and immune function: central pathways to morbidity and mortality. J. Psychosom. Res. 53: 873-876.
134. Silverman, M.N. et al. 2004. Characterization of an interleukin-6- and adrenocorticotropin-dependent, immune-to-adrenal pathway during viral infection. Endocrinology 145: 3580-3589.
135. Capuron, L. et al. 2002. Treatment of cytokineinduced depression. Brain Behav. Immun. 16: 575-580.
136. Maddock, C. et al. 2005. Psychopathological symptoms during interferon-alpha and ribavirin treatment: effects on virologic response. Mol. Psychiatry 10: 332-333.
137. Raison, C.L. et al. 2005. Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. J. Clin. Psychiatry 66: 41-48.
138. Raison, C.L. & A.H. Miller. 2003. When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders. Am. J. Psychiatry 160: 1554-1565.
139. Silverman, M.N. et al. 2007. Endogenous glucocorticoids protect against TNF-alpha-induced increases in anxiety-like behavior in virally infected mice. Mol. Psychiatry 12: 408-417.
140. Maes, M. et al. 1995. Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. J. Affect. Disord. 34: 301-309.
141. Levine, J. et al. 1999. Cerebrospinal cytokine levels in patients with acute depression. Neuropsychobiology 40: 171-176. (Pubitemid 29515729)
142. Cizza, G. et al. 2008. Elevated neuroimmune biomarkers in sweat patches and plasma of premenopausal women with major depressive disorder in remission: the P.O.W.E.R. study. Biol. Psychiatry 64: 907-911.
143. Carpenter, L.L. et al. 2004. Cerebrospinal fluid interleukin (IL)-6 in unipolar major depression. J. Affect. Disord. 79: 285-289.
144. Anisman, H. et al. 1999. Endocrine and cytokine correlates of major depression and dysthymia with typical or atypical features. Mol. Psychiatry 4: 182-188.
145. Brambilla, F., P. Monteleone & M. Maj. 2004. Interleukin-1beta and tumor necrosis factor-alpha in children with major depressive disorder or dysthymia. J. Affect. Disord. 78: 273-277.
146. Marques-Deak, A.H. et al. 2007. Cytokine profiles in women with different subtypes of major depressive disorder. J. Psychiatr. Res. 41: 152-159.
147. Marques-Deak, A. et al. 2006. Measurement of cytokines in sweat patches and plasma in healthy women: validation in a controlled study. J. Immunol. Methods. 315: 99-109.
148. Phillips, T.M. 2001. Multi-analyte analysis of biological fluids with a recycling immunoaffinity column array. J. Biochem. Biophys. Methods. 49: 253-262.
149. Eskandari, F. et al. 2007. Low bone mass in premenopausal women with depression. Arch. Intern. Med. 167: 2329-2336.
150. Webster, J.I., L. Tonelli & E.M. Sternberg. 2002. Neuroendocrine regulation of immunity. Annu. Rev. Immunol. 20: 125-163.
151. Silverman, M.N., B.D. Pearce & A.H. Miller. 2003. Cytokines and HPA axis regulation. In Cytokines and Mental Health. Z.Kronfol, Ed.: 85-122. Kluwer Academic Publishers. Norwell, MA.
152. Thayer, J.F. & E. Sternberg. 2006. Beyond heart rate variability: vagal regulation of allostatic systems. Ann. N. Y. Acad. Sci. 1088: 361-372